Lutetium dotatate lu-177
EndolucinBeta, Lumark (lutetium dotatate lu-177) is an unknown pharmaceutical. Lutetium dotatate lu-177 was first approved as Lumark on 2015-06-18. It has been approved in Europe to treat radionuclide imaging.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| diagnosis | D003933 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
69 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Papillary thyroid cancer | D000077273 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 13 | 19 | 6 | — | 8 | 40 |
| Carcinoid tumor | D002276 | D3A.00 | — | 3 | 1 | — | — | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine carcinoma | D018278 | 1 | 6 | — | — | — | 6 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 4 | — | — | 1 | 6 |
| Paraganglioma | D010235 | 1 | 4 | — | — | — | 4 | ||
| Pheochromocytoma | D010673 | 1 | 3 | — | — | — | 3 | ||
| Meningioma | D008579 | EFO_0003098 | D32.9 | 1 | 3 | — | — | — | 3 |
| Neoplasms | D009369 | C80 | — | 2 | — | — | 1 | 3 | |
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | 1 | 2 | — | — | — | 2 |
| Neuroblastoma | D009447 | EFO_0000621 | 1 | 1 | — | — | — | 2 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Pituitary neoplasms | D010911 | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thymoma | D013945 | 1 | — | — | — | — | 1 | ||
| Mesothelioma | D008654 | C45 | 1 | — | — | — | — | 1 | |
| Glioblastoma | D005909 | EFO_0000515 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 1 | 1 |
| Gastrointestinal neoplasms | D005770 | C26.9 | — | — | — | — | 1 | 1 | |
| Digestive system neoplasms | D004067 | — | — | — | — | 1 | 1 | ||
| Gastrointestinal diseases | D005767 | — | — | — | — | 1 | 1 | ||
| Germ cell and embryonal neoplasms | D009373 | — | — | — | — | 1 | 1 | ||
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 1 | 1 |
| Neoplasms by histologic type | D009370 | — | — | — | — | 1 | 1 | ||
| Intestinal neoplasms | D007414 | C26.0 | — | — | — | — | 1 | 1 | |
| Endocrine gland neoplasms | D004701 | EFO_0003769 | D35 | — | — | — | — | 1 | 1 |
| Neoplasms by site | D009371 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LUTETIUM DOTATATE LU-177 |
| INN | lutetium (177lu) oxodotreotide |
| Description | Lutetium (177Lu) oxodotreotide (INN) or 177Lu DOTA-TATE, trade name Lutathera, is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). Specifically, it is used in the treatment of cancers which express somatostatin receptors.
|
| Classification | Unknown |
| Drug class | Antineoplastic agent |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 437608-50-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989924 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB13985 |
| UNII ID | AE221IM3BB (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 55 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more